Chemotherapy Tolerance After Radioimmunotherapy with90Y-CC49 Monoclonal Antibody in Patients with Advanced Non-Small Cell Lung Cancer: Clinical Effects and Hematologic Toxicity
- 1 June 2003
- journal article
- research article
- Published by Mary Ann Liebert Inc in Cancer Biotherapy & Radiopharmaceuticals
- Vol. 18 (3), 317-325
- https://doi.org/10.1089/108497803322285071
Abstract
The purpose of this retrospective analysis was to evaluate the hematologic toxicity and clinical outcome of salvage chemotherapy following (90)Y-CC49 radioimmunotherapy (RIT) in patients with non-small cell lung cancer (NSCLC). Sixteen patients from a total of 37 who were enrolled in a phase I trial of (90)Y-CC49 monoclonal therapy were treated with post-RIT salvage chemotherapy at our institution. Five patients had received chest radiation therapy prior to RIT, and seven patients had prior chemotherapy. The majority of these patients were treated with doses of (90)Y of >/= 14 mCi/m(2) (8-20 mCi/m(2)), and four of them received concurrent 96-hour taxol infusion. The maximum tolerated dose of this study was exceeded at 17 mCi/m(2), and grade 4 thrombocytopenia/neutropenia were the dose-limiting toxicities. Twelve patients received one chemotherapy regimen as salvage therapy, and four patients had more than one regimen. Four patients (25%) experienced reversible grade 4 neutropenia, but no grade 4 thrombocytopenia was observed. Five patients had stable disease. The median survival from start of salvage therapy was 5.5 months. Our data suggest that therapy with RIT did not significantly affect survival of these patients. Taking into consideration the potential clinical relevance of integration of RIT with other treatment modalities, it is important to expand this clinical experience in order to support combined modality strategies.Keywords
This publication has 13 references indexed in Scilit:
- Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung CancerThe New England Journal of Medicine, 2002
- Pivotal Study of Iodine I 131 Tositumomab for Chemotherapy-Refractory Low-Grade or Transformed Low-Grade B-Cell Non-Hodgkin’s LymphomasJournal of Clinical Oncology, 2001
- Gene transfer into murine hematopoietic stem cells with helper-free foamy virus vectorsBlood, 2001
- Intraperitoneal Radioimmunochemotherapy of Ovarian Cancer: A Phase I StudyCancer Biotherapy & Radiopharmaceuticals, 2001
- Phase I/II Trial of IDEC-Y2B8 Radioimmunotherapy for Treatment of Relapsed or Refractory CD20+B-Cell Non-Hodgkin's LymphomaJournal of Clinical Oncology, 1999
- Correlation of Toxicity with Treatment Parameters for 131I-CC49 Radioimmunotherapy in Three Phase II Clinical TrialsCancer Biotherapy & Radiopharmaceuticals, 1997
- Fludarabine, mitoxantrone, and dexamethasone: an effective new regimen for indolent lymphoma.Journal of Clinical Oncology, 1996
- Radioimmunotherapy: recent results and future directions.Journal of Clinical Oncology, 1996
- Treatment of refractory non-Hodgkin's lymphoma with radiolabeled MB-1 (anti-CD37) antibody.Journal of Clinical Oncology, 1989
- Results of MIME salvage regimen for recurrent or refractory lymphoma.Journal of Clinical Oncology, 1987